Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer

Niranjan J. Sathianathen, Subodh Regmi, Shilpa Gupta, Badrinath R. Konety

Research output: Contribution to journalReview article

Abstract

This article provides a comprehensive review of the available data for immunotherapy being used as a salvage treatment in non–muscle-invasive bladder cancer. The literature demonstrates that the immune system has an important role in bladder cancer progression. Initial results from studies using checkpoint inhibitors, recombinant interferon-α2b protein, and oncolytic adenoviruses have shown promising responses with acceptable toxicities. However, the majority of the current data arises from small trials with limited follow-up. There are currently several ongoing studies in this setting, which we await completion, to increase our understanding of immunotherapy as a salvage treatment in non–muscle-invasive bladder cancer.

Original languageEnglish (US)
Pages (from-to)103-110
Number of pages8
JournalUrologic Clinics of North America
Volume47
Issue number1
DOIs
StatePublished - Feb 2020

Fingerprint

Salvage Therapy
Urinary Bladder Neoplasms
Immunotherapy
Adenoviridae
Interferons
Immune System
Proteins

Keywords

  • Bladder cancer
  • Immunotherapy
  • Non–muscle-invasive bladder cancer
  • Oncology

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer. / Sathianathen, Niranjan J.; Regmi, Subodh; Gupta, Shilpa; Konety, Badrinath R.

In: Urologic Clinics of North America, Vol. 47, No. 1, 02.2020, p. 103-110.

Research output: Contribution to journalReview article

@article{caaffd3ed07d4db69964f325c35e6fe8,
title = "Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer",
abstract = "This article provides a comprehensive review of the available data for immunotherapy being used as a salvage treatment in non–muscle-invasive bladder cancer. The literature demonstrates that the immune system has an important role in bladder cancer progression. Initial results from studies using checkpoint inhibitors, recombinant interferon-α2b protein, and oncolytic adenoviruses have shown promising responses with acceptable toxicities. However, the majority of the current data arises from small trials with limited follow-up. There are currently several ongoing studies in this setting, which we await completion, to increase our understanding of immunotherapy as a salvage treatment in non–muscle-invasive bladder cancer.",
keywords = "Bladder cancer, Immunotherapy, Non–muscle-invasive bladder cancer, Oncology",
author = "Sathianathen, {Niranjan J.} and Subodh Regmi and Shilpa Gupta and Konety, {Badrinath R.}",
year = "2020",
month = "2",
doi = "10.1016/j.ucl.2019.09.012",
language = "English (US)",
volume = "47",
pages = "103--110",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer

AU - Sathianathen, Niranjan J.

AU - Regmi, Subodh

AU - Gupta, Shilpa

AU - Konety, Badrinath R.

PY - 2020/2

Y1 - 2020/2

N2 - This article provides a comprehensive review of the available data for immunotherapy being used as a salvage treatment in non–muscle-invasive bladder cancer. The literature demonstrates that the immune system has an important role in bladder cancer progression. Initial results from studies using checkpoint inhibitors, recombinant interferon-α2b protein, and oncolytic adenoviruses have shown promising responses with acceptable toxicities. However, the majority of the current data arises from small trials with limited follow-up. There are currently several ongoing studies in this setting, which we await completion, to increase our understanding of immunotherapy as a salvage treatment in non–muscle-invasive bladder cancer.

AB - This article provides a comprehensive review of the available data for immunotherapy being used as a salvage treatment in non–muscle-invasive bladder cancer. The literature demonstrates that the immune system has an important role in bladder cancer progression. Initial results from studies using checkpoint inhibitors, recombinant interferon-α2b protein, and oncolytic adenoviruses have shown promising responses with acceptable toxicities. However, the majority of the current data arises from small trials with limited follow-up. There are currently several ongoing studies in this setting, which we await completion, to increase our understanding of immunotherapy as a salvage treatment in non–muscle-invasive bladder cancer.

KW - Bladder cancer

KW - Immunotherapy

KW - Non–muscle-invasive bladder cancer

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=85075068012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075068012&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2019.09.012

DO - 10.1016/j.ucl.2019.09.012

M3 - Review article

C2 - 31757293

AN - SCOPUS:85075068012

VL - 47

SP - 103

EP - 110

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 1

ER -